CoChat
Sign Up
Cited by 141Parkinson's Disease Mechanisms and TreatmentsMicroRNA in disease regulationNeuroinflammation and Neurodegeneration Mechanisms

MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson’s Disease and Multiple System Atrophy

Open access
Marques, Tainá M., Kuiperij, H. Bea, Bruinsma, Ilona B., van Rumund, Anouke, Aerts, Marjolein B., Esselink, Rianne A. J., Bloem, Bas R., Verbeek, Marcel M.·2017·Molecular Neurobiology
DOI 10.1007/s12035-016-0253-0PMC PMC5684261
Open this paper in CoChat — free accountOpen PDF

Abstract

Parkinson's disease (PD) and multiple system atrophy (MSA) are both part of the spectrum of neurodegenerative movement disorders and α-synucleinopathies with overlap of symptoms especially at early stages of the disease but with distinct disease progression and responses to dopaminergic treatment. Therefore, having biomarkers that specifically classify patients, which could discriminate PD from MSA, would be very useful. MicroRNAs (miRNAs) regulate protein translation and are observed in biological fluids, including cerebrospinal fluid (CSF), and may therefore have potential as biomarkers of disease. The aim of our study was to determine if miRNAs in CSF could be used as biomarkers for either PD or MSA. Using quantitative PCR (qPCR), we evaluated expression levels of 10 miRNAs in CSF patient samples from PD (n = 28), MSA (n = 17), and non-neurological controls (n = 28). We identified two miRNAs (miR-24 and miR-205) that distinguished PD from controls and four miRNAs that differentiated MSA from controls (miR-19a, miR-19b, miR-24, and miR-34c). Combinations of miRNAs accurately discriminated either PD (area under the curve (AUC) = 0.96) or MSA (AUC = 0.86) from controls. In MSA, we also observed that miR-24 and miR-148b correlated with cerebellar ataxia symptoms, suggesting that these miRNAs are involved in cerebellar degeneration in MSA. Our findings support the potential of miRNA panels as biomarkers for movement disorders and may provide more insights into the pathological mechanisms related to these disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12035-016-0253-0

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The discrepancy between CSF biomarker studies may be in part due to the intrinsic variability of miRNA itself.

    “Taken together, our data suggests that the discrepancy between CSF biomarker studies may be in part due to the intrinsic variability of miRNA itself43,44.”

    From Intra- and Inter-individual Variability of microRNA Levels in Human Cerebrospinal Fluid: Critical Implications for Biomarker Discovery (2017) · cites this paper as [44]

    The Discussion’s Study Limitations section (page not provided) says CSF miRNA measurements can vary across studies, citing sample processing, normalization methods, and qPCR variability. It does not identify intrinsic variability of miRNA itself as the cause of those discrepancies. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 38

  1. [1]Kalia LV Lang AE Parkinson’s disease Lancet 2015 386 9996 896 912 10.1016/S0140-6736(14)61393-3 25904081 · DOI
  2. [2]Poewe W Non-motor symptoms in Parkinson’s disease Eur J Neurol 2008 15 Suppl 1 14 20 10.1111/j.1468-1331.2008.02056.x 18353132 · DOI
  3. [3]Stefanova N Bucke P Duerr S Wenning GK Multiple system atrophy: an update Lancet Neurol 2009 8 12 1172 1178 10.1016/S1474-4422(09)70288-1 19909915 · DOI
  4. [4]Gilman S Wenning GK Low PA Brooks DJ Mathias CJ Trojanowski JQ Wood NW Colosimo C Durr A Fowler CJ Kaufmann H Klockgether T Lees A Poewe W Quinn N Revesz T Robertson D Sandroni P Seppi K Vidailhet M Second consensus statement on the diagnosis of multiple system atrophy Neurology 2008 71 9 670 676 10.1212/01.wnl.0000324625.00404.15 18725592 PMC2676993 · DOI · Paper page
  5. [5]Hughes AJ Daniel SE Kilford L Lees AJ Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases J Neurol Neurosurg Psychiatry 1992 55 3 181 184 10.1136/jnnp.55.3.181 1564476 PMC1014720 · DOI · Paper page
  6. [6]Magdalinou N Lees AJ Zetterberg H Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions J Neurol Neurosurg Psychiatry 2014 85 10 1065 1075 10.1136/jnnp-2013-307539 24691581 PMC4173749 · DOI
  7. [7]Herbert MK Aerts MB Beenes M Norgren N Esselink RA Bloem BR Kuiperij HB Verbeek MM CSF neurofilament light chain but not FLT3 ligand discriminates parkinsonian disorders Front Neurol 2015 6 91 10.3389/fneur.2015.00091 25999911 PMC4419719 · DOI
  8. [8]Herbert MK Eeftens JM Aerts MB Esselink RA Bloem BR Kuiperij HB Verbeek MM CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls Parkinsonism Relat Disord 2014 20 1 112 115 10.1016/j.parkreldis.2013.09.003 24075122 · DOI
  9. [9]Abdo WF Bloem BR Van Geel WJ Esselink RA Verbeek MM CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson’s disease Neurobiol Aging 2007 28 5 742 747 10.1016/j.neurobiolaging.2006.03.010 16678934 · DOI
  10. [10]Parnetti L Castrioto A Chiasserini D Persichetti E Tambasco N El-Agnaf O Calabresi P Cerebrospinal fluid biomarkers in Parkinson disease Nat Rev Neurol 2013 9 3 131 140 10.1038/nrneurol.2013.10 23419373 · DOI · Paper page
  11. [11]Maciotta S Meregalli M Torrente Y The involvement of microRNAs in neurodegenerative diseases Front Cell Neurosci 2013 7 265 10.3389/fncel.2013.00265 24391543 PMC3867638 · DOI
  12. [12]Bartel DP MicroRNAs: genomics, biogenesis, mechanism, and function Cell 2004 116 2 281 297 10.1016/S0092-8674(04)00045-5 14744438 · DOI
  13. [13]Mitchell PS Parkin RK Kroh EM Fritz BR Wyman SK Pogosova-Agadjanyan EL Peterson A Noteboom J O’Briant KC Allen A Lin DW Urban N Drescher CW Knudsen BS Stirewalt DL Gentleman R Vessella RL Nelson PS Martin DB Tewari M Circulating microRNAs as stable blood-based markers for cancer detection Proc Natl Acad Sci U S A 2008 105 30 10513 10518 10.1073/pnas.0804549105 18663219 PMC2492472 · DOI · Paper page
  14. [14]Heman-Ackah SM Hallegger M Rao MS Wood MJ RISC in PD: the impact of microRNAs in Parkinson’s disease cellular and molecular pathogenesis Front Mol Neurosci 2013 6 40 10.3389/fnmol.2013.00040 24312000 PMC3834244 · DOI
  15. [15]Minones-Moyano E Porta S Escaramis G Rabionet R Iraola S Kagerbauer B Espinosa-Parrilla Y Ferrer I Estivill X Marti E MicroRNA profiling of Parkinson’s disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function Hum Mol Genet 2011 20 15 3067 3078 10.1093/hmg/ddr210 21558425 · DOI
  16. [16]Kim J Inoue K Ishii J Vanti WB Voronov SV Murchison E Hannon G Abeliovich A A MicroRNA feedback circuit in midbrain dopamine neurons Science 2007 317 5842 1220 1224 10.1126/science.1140481 17761882 PMC2782470 · DOI · Paper page
  17. [17]Cho HJ Liu G Jin SM Parisiadou L Xie C Yu J Sun L Ma B Ding J Vancraenenbroeck R Lobbestael E Baekelandt V Taymans JM He P Troncoso JC Shen Y Cai H MicroRNA-205 regulates the expression of Parkinson’s disease-related leucine-rich repeat kinase 2 protein Hum Mol Genet 2013 22 3 608 620 10.1093/hmg/dds470 23125283 PMC3542867 · DOI
  18. [18]Martins M Rosa A Guedes LC Fonseca BV Gotovac K Violante S Mestre T Coelho M Rosa MM Martin ER Vance JM Outeiro TF Wang L Borovecki F Ferreira JJ Oliveira SA Convergence of miRNA expression profiling, alpha-synuclein interacton and GWAS in Parkinson’s disease PLoS One 2011 6 10 e25443 10.1371/journal.pone.0025443 22003392 PMC3189215 · DOI
  19. [19]Botta-Orfila T Morato X Compta Y Lozano JJ Falgas N Valldeoriola F Pont-Sunyer C Vilas D Mengual L Fernandez M Molinuevo JL Antonell A Marti MJ Fernandez-Santiago R Ezquerra M Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson’s disease J Neurosci Res 2014 92 8 1071 1077 10.1002/jnr.23377 24648008 · DOI
  20. [20]Burgos K Malenica I Metpally R Courtright A Rakela B Beach T Shill H Adler C Sabbagh M Villa S Tembe W Craig D Van Keuren-Jensen K Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer’s and Parkinson’s diseases correlate with disease status and features of pathology PLoS One 2014 9 5 e94839 10.1371/journal.pone.0094839 24797360 PMC4010405 · DOI · Paper page
  21. [21]Vallelunga A Ragusa M Di Mauro S Iannitti T Pilleri M Biundo R Weis L Di Pietro C De Iuliis A Nicoletti A Zappia M Purrello M Antonini A Identification of circulating microRNAs for the differential diagnosis of Parkinson’s disease and multiple system atrophy Front Cell Neurosci 2014 8 156 10.3389/fncel.2014.00156 24959119 PMC4051126 · DOI
  22. [22]Aerts MB Esselink RA Abdo WF Meijer FJ Drost G Norgren N Janssen MJ Borm GF Bloem BR Verbeek MM Ancillary investigations to diagnose parkinsonism: a prospective clinical study J Neurol 2015 262 2 346 356 10.1007/s00415-014-7568-4 25381460 · DOI
  23. [23]Hoehn MM MD Y Parkinsonism: onset, progression, and mortality. 1967 Neurology 2001 57 10 Suppl 3 S11 S26 11775596
  24. [24]Movement Disorder Society Task Force on Rating Scales for Parkinson’s D The Unified Parkinson’s Disease Rating Scale (UPDRS): status and recommendations Mov Disord: Off J Mov Disord Soc 2003 18 7 738 750 10.1002/mds.10473 12815652 · DOI
  25. [25]Trouillas P Takayanagi T Hallett M Currier RD Subramony SH Wessel K Bryer A Diener HC Massaquoi S Gomez CM Coutinho P Ben Hamida M Campanella G Filla A Schut L Timann D Honnorat J Nighoghossian N Manyam B International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology J Neurol Sci 1997 145 2 205 211 10.1016/S0022-510X(96)00231-6 9094050 · DOI
  26. [26]Folstein MF Robins LN Helzer JE The Mini-Mental State Examination Arch Gen Psychiatry 1983 40 7 812 10.1001/archpsyc.1983.01790060110016 6860082 · DOI
  27. [27]Muller M Jakel L Bruinsma IB Claassen JA Kuiperij HB Verbeek MM MicroRNA-29a is a candidate biomarker for Alzheimer’s disease in cell-free cerebrospinal fluid Mol Neurobiol 2015 PMC4902829 25895659
  28. [28]Muller M Kuiperij HB Claassen JA Kusters B Verbeek MM MicroRNAs in Alzheimer’s disease: differential expression in hippocampus and cell-free cerebrospinal fluid Neurobiol Aging 2014 35 1 152 158 10.1016/j.neurobiolaging.2013.07.005 23962497 · DOI
  29. [30]Agarwal V, Bell GW, Nam JW, Bartel DP (2015) Predicting effective microRNA target sites in mammalian mRNAs. eLife 4. doi:10.7554/eLife.05005 PMC4532895 26267216 · DOI · Paper page
  30. [31]Paraskevopoulou MD Georgakilas G Kostoulas N Vlachos IS Vergoulis T Reczko M Filippidis C Dalamagas T Hatzigeorgiou AG DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows Nucleic Acids Res 2013 41 W169 W173 10.1093/nar/gkt393 23680784 PMC3692048 · DOI
  31. [32]Reczko M Maragkakis M Alexiou P Grosse I Hatzigeorgiou AG Functional microRNA targets in protein coding sequences Bioinformatics 2012 28 6 771 776 10.1093/bioinformatics/bts043 22285563 · DOI
  32. [33]Fernandez-Santiago R Iranzo A Gaig C Serradell M Fernandez M Tolosa E Santamaria J Ezquerra M MicroRNA association with synucleinopathy conversion in rapid eye movement behavior disorder Ann Neurol 2015 77 5 895 901 10.1002/ana.24384 25675938 · DOI
  33. [34]Gugger JJ Wagner ML Rapid eye movement sleep behavior disorder Ann Pharmacother 2007 41 11 1833 1841 10.1345/aph.1H587 17925503 · DOI
  34. [35]Gui YX Liu H Zhang LS Lv W Hu XY Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease Oncotarget 2015 6 35 37043 37053 10.18632/oncotarget.6158 26497684 PMC4741914 · DOI · Paper page
  35. [37]da Costa CA Sunyach C Giaime E West A Corti O Brice A Safe S Abou-Sleiman PM Wood NW Takahashi H Goldberg MS Shen J Checler F Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson’s disease Nat Cell Biol 2009 11 11 1370 1375 10.1038/ncb1981 19801972 PMC2952934 · DOI
  36. [38]Fan J Ren H Jia N Fei E Zhou T Jiang P Wu M Wang G DJ-1 decreases Bax expression through repressing p53 transcriptional activity J Biol Chem 2008 283 7 4022 4030 10.1074/jbc.M707176200 18042550 · DOI
  37. [39]Alves da Costa C Paitel E Vincent B Checler F Alpha-synuclein lowers p53-dependent apoptotic response of neuronal cells. Abolishment by 6-hydroxydopamine and implication for Parkinson’s disease J Biol Chem 2002 277 52 50980 50984 10.1074/jbc.M207825200 12397073 · DOI
  38. [40]Kabaria S Choi DC Chaudhuri AD Mouradian MM Junn E Inhibition of miR-34b and miR-34c enhances alpha-synuclein expression in Parkinson’s disease FEBS Lett 2015 589 3 319 325 10.1016/j.febslet.2014.12.014 25541488 PMC4306645 · DOI

Cited by

Sorted by citations

Authors
Marques, T. M., Kuiperij, H. B., Bruinsma, I. B., van Rumund, A., Aerts, M. B., Esselink, R. A. J., Bloem, B. R., & Verbeek, M. M.
Affiliations
  • Radboud University Medical Center (NL)
  • Radboud University Nijmegen (NL)
Corresponding author
Verbeek, Marcel M.
ORCID
Venue
Molecular Neurobiology
Publisher
Springer Science and Business Media LLC
Published
2016-11-14
Volume
54
Issue
10
Pages
7736-7745
ISSN
  • 0893-7648 (ISSN-L)
  • 1559-1182
DOI
10.1007/s12035-016-0253-0
PMC
PMC5684261
OpenAlex
W2550142622
Cited by
141
References
2
Citations by year
2026: 7 · 2025: 10 · 2024: 14 · 2023: 16 · 2022: 17 · 2021: 13 · 2020: 15 · 2019: 18 · 2018: 15 · 2017: 15
FWCI
12.03
Type
journal article
Language
en
Open access
Licence
Locations
  • Molecular Neurobiology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion, other-oa)
Funders
Conselho Nacional de Desenvolvimento Científico e Tecnológico (249032/2013-9)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
microRNA, cerebrospinal fluid, Parkinson's disease, multiple system atrophy, biomarkers, differential diagnosis, miR-24, miR-205, miR-19a, miR-19b, miR-34c, miR-148b, cerebellar ataxia, cerebellar degeneration, synucleinopathies, neurodegenerative movement disorders
MeSH terms
Aged, Female, Humans, Male, Middle Aged, Parkinson Disease, Biomarkers, Multiple System Atrophy, MicroRNAs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review